A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
A Multi-center, Prospective, Longitudinal Cohort Study to Collect Immunological and Clinical Data on Epstein-Barr Virus (EBV) Reactivation in EBV Seropositive Male and Female Adults Aged 18 to 29 Years
Sanofi Pasteur, a Sanofi Company
100 participants
Apr 20, 2026
OBSERVATIONAL
Conditions
Summary
This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years. This study will follow a cohort of approximately 100 EBV seropositive adults 18 to 29 years of age in Australia over a 6 or 12-month period. Participants will not receive any study intervention (eg, study treatments, vaccines).
Eligibility
Inclusion Criteria3
- Aged 18 to 29 years on the day of inclusion
- Participants who are healthy as determined by medical evaluation including medical history and physical examination
- Participants who are EBV seropositive based on serology testing
Exclusion Criteria2
- Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives, including planning to leave the area of the study before the end of study period
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
It consists of prospective blood and saliva collections. Study without any IMP administration.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07536048